Business Context and Reporting Period
Compugen Ltd., a foreign private issuer, filed this Form 6-K on April 18, 2016, covering the month of April 2016. The filing reports on a significant development in the Company's Research and Development Collaboration and License Agreement with Bayer Pharma AG.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the period. The only specific financial figure disclosed is a milestone payment of $400,000 to be received from Bayer.
Material Changes
- Milestone Achievement: On April 18, 2016, Compugen announced the achievement of the first preclinical milestone for CGEN-15022, a checkpoint protein candidate.
- Contract Amendment: On April 17, 2016, Compugen and Bayer entered into an amendment to their 2013 Agreement to modify provisions related to this specific milestone.
- Revenue Impact: As a result of the milestone achievement, Compugen is entitled to receive a $400,000 payment under the amended Agreement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, general outlook statements, or a discussion of risks and contingencies beyond the specific transaction details. The document focuses solely on the execution of the contract amendment and the resulting milestone payment.
Investor Verification Checklist
- Verify the terms of the amended Agreement between Compugen and Bayer regarding CGEN-15022.
- Confirm the receipt of the $400,000 milestone payment in subsequent financial reports.
- Review the full text of the press release filed as Exhibit 99.1 for additional technical details on the preclinical milestone.